Thanks for participating in our interactive
clinical knowledge question.
Question: A 55-year-old female on tirzepetide for obesity presents for follow-up, after having experienced the expected weight loss with eight months of therapy. She has questions regarding the recommended duration of treatment. In addition to continued attention to diet and exercise, how do you counsel her?
{{APercent}}% of
Medical Professionals
Chose A
{{BPercent}}% of
Medical Professionals
Chose B
{{CPercent}}% of
Medical Professionals
Chose C
Correct Answer: C. Glucagon-like peptide 1-based therapies (tirzepetide, semaglutide) for the treatment of obesity result in substantial weight loss, but stopping treatment results in weight regain. Most individuals with obesity who opt for pharmacotherapy will require long-term treatment for weight loss maintenance.
As you can see from the results above, it's a challenge to always identify the correct diagnosis.
Do you want to dive deeper on topics like this and further enhance your medical knowledge? You can view our sample topics for free and see how UpToDate provides you with the evidence-based information you need to support your clinical decisions.